Trial Search Results
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
In this study, patients with advanced solid tumors will undergo [18F]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.
Stanford is currently not accepting patients for this trial.
CellSight Technologies, Inc.
Collaborator: Stanford University
- Drug: [18F]F-AraG
- Solid tumor with planned CkIT
- Must be >18 years old
- Signed Informed Consent Form
- Patient must have two qualifying lesions
- Patient is pregnant or breast feeding
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study